Three year data have been required in general in the setting of adjuva的简体中文翻译

Three year data have been required

Three year data have been required in general in the setting of adjuvant treatment of breast cancer. The robustness of the data for the 2 year is acknolewdged, but due to the study conduct after the 2 year phase (see above), the extent of benefit at five years remains uncertain; however, maintained benefit is expected, especially in the restricted HRc+ population with a larger effect size. The limited tolerability of Nerlynx due to diarrhoea, frequently leading to treatment discontinuation, is recognized as an important limitation on clinical utility. However, this side effect is reversible on discontinuation and further studies to identify appropriate strategies for anti-diarrhoeal management are underway (see RMP). Furthermore, no safety issues of major concern to negate the demonstrated benefit have emerged. At present, from a patient and clinical perspective, as long as benefits, risks, and uncertainties are clearly understood, it is considered that meaningful treatment decisions can be made and that treatment with neratinib can be a good option for some patients. Consequently, while it is recognized that adjuvant treatment with Nerlynx may not be appropriate for every patient, it is considered a reasonable treatment option on a case by case basis, as extended adjuvant therapy for HER2+, HRc+ early breast cancer (see PI). The clinical utility is expected to improve with optimisation of anti-diarrhoeal management.
0/5000
源语言: -
目标语言: -
结果 (简体中文) 1: [复制]
复制成功!
三年数据已经要求一般在乳腺癌的辅助治疗的设置。对于2年的数据的稳健性acknolewdged,但由于2年期后的学习行为(见上文),受益于五年程度仍然不明朗; 然而,保持益处的预期,尤其是在限制HRC +群体具有较大影响的大小。Nerlynx因腹泻有限的耐受性,常常导致治疗中断,被确认为临床应用的一个重要限制。然而,这种副作用是停药,并进一步研究可逆确定适当的战略,抗腹泻管理正在进行当中(见RMP)。此外,主要关注的否定展示利用的无安全问题已经出现。现在,从病人和临床的角度来看,只要收益,风险和不确定性都清楚地理解,可以认为有意义的处理决定,可以作出,那替尼是治疗可以对某些患者一个很好的选择。因此,虽然应当认识到,与Nerlynx辅助治疗可能不适合于每一个病人,它被认为是在由个案基础上合理的治疗选择,因为延长的辅助治疗HER2 +,HRC +早期乳腺癌(参见PI)。临床应用有望随着抗腹泻管理的优化来改善。而应当认识到,与Nerlynx辅助治疗可能不适合用于每一个病人,它被认为是在由个案基础上合理的治疗选择,因为延长的辅助治疗HER2 +,HRC +早期乳腺癌(参见PI)。临床应用有望随着抗腹泻管理的优化来改善。而应当认识到,与Nerlynx辅助治疗可能不适合用于每一个病人,它被认为是在由个案基础上合理的治疗选择,因为延长的辅助治疗HER2 +,HRC +早期乳腺癌(参见PI)。临床应用有望随着抗腹泻管理的优化来改善。
正在翻译中..
结果 (简体中文) 2:[复制]
复制成功!
Three year data have been required in general in the setting of adjuvant treatment of breast cancer. The robustness of the data for the 2 year is acknolewdged, but due to the study conduct after the 2 year phase (see above), the extent of benefit at five years remains uncertain; however, maintained benefit is expected, especially in the restricted HRc+ population with a larger effect size. The limited tolerability of Nerlynx due to diarrhoea, frequently leading to treatment discontinuation, is recognized as an important limitation on clinical utility. However, this side effect is reversible on discontinuation and further studies to identify appropriate strategies for anti-diarrhoeal management are underway (see RMP). Furthermore, no safety issues of major concern to negate the demonstrated benefit have emerged. At present, from a patient and clinical perspective, as long as benefits, risks, and uncertainties are clearly understood, it is considered that meaningful treatment decisions can be made and that treatment with neratinib can be a good option for some patients. Consequently, while it is recognized that adjuvant treatment with Nerlynx may not be appropriate for every patient, it is considered a reasonable treatment option on a case by case basis, as extended adjuvant therapy for HER2+, HRc+ early breast cancer (see PI). The clinical utility is expected to improve with optimisation of anti-diarrhoeal management.
正在翻译中..
结果 (简体中文) 3:[复制]
复制成功!
乳腺癌的辅助治疗一般需要三年的数据。2年数据的稳健性得到确认,但由于2年阶段(见上文)后的研究进行,5年的受益程度仍不确定;然而,预计将维持受益,特别是在影响规模较大的受限HRc+人群中。由于腹泻导致的Nerlynx耐受性有限,常常导致治疗中止,被认为是对临床应用的一个重要限制。然而,这种副作用在停药时是可逆的,目前正在进行进一步的研究,以确定适当的抗腹泻治疗策略(见RMP)。此外,没有出现任何重大的安全问题来否定已证明的效益。目前,从患者和临床的角度来看,只要清楚地了解益处、风险和不确定性,就可以做出有意义的治疗决定,对某些患者来说,尼拉替尼治疗是一个不错的选择。因此,虽然人们认识到Nerlynx辅助治疗可能不适合每一个患者,但作为HER2+,HRc+早期乳腺癌的扩展辅助治疗(见PI),它被视为逐案的合理治疗选择。随着抗腹泻管理的优化,临床应用有望得到改善。
正在翻译中..
 
其它语言
本翻译工具支持: 世界语, 丹麦语, 乌克兰语, 乌兹别克语, 乌尔都语, 亚美尼亚语, 伊博语, 俄语, 保加利亚语, 信德语, 修纳语, 僧伽罗语, 克林贡语, 克罗地亚语, 冰岛语, 加利西亚语, 加泰罗尼亚语, 匈牙利语, 南非祖鲁语, 南非科萨语, 卡纳达语, 卢旺达语, 卢森堡语, 印地语, 印尼巽他语, 印尼爪哇语, 印尼语, 古吉拉特语, 吉尔吉斯语, 哈萨克语, 土库曼语, 土耳其语, 塔吉克语, 塞尔维亚语, 塞索托语, 夏威夷语, 奥利亚语, 威尔士语, 孟加拉语, 宿务语, 尼泊尔语, 巴斯克语, 布尔语(南非荷兰语), 希伯来语, 希腊语, 库尔德语, 弗里西语, 德语, 意大利语, 意第绪语, 拉丁语, 拉脱维亚语, 挪威语, 捷克语, 斯洛伐克语, 斯洛文尼亚语, 斯瓦希里语, 旁遮普语, 日语, 普什图语, 格鲁吉亚语, 毛利语, 法语, 波兰语, 波斯尼亚语, 波斯语, 泰卢固语, 泰米尔语, 泰语, 海地克里奥尔语, 爱尔兰语, 爱沙尼亚语, 瑞典语, 白俄罗斯语, 科西嘉语, 立陶宛语, 简体中文, 索马里语, 繁体中文, 约鲁巴语, 维吾尔语, 缅甸语, 罗马尼亚语, 老挝语, 自动识别, 芬兰语, 苏格兰盖尔语, 苗语, 英语, 荷兰语, 菲律宾语, 萨摩亚语, 葡萄牙语, 蒙古语, 西班牙语, 豪萨语, 越南语, 阿塞拜疆语, 阿姆哈拉语, 阿尔巴尼亚语, 阿拉伯语, 鞑靼语, 韩语, 马其顿语, 马尔加什语, 马拉地语, 马拉雅拉姆语, 马来语, 马耳他语, 高棉语, 齐切瓦语, 等语言的翻译.

Copyright ©2024 I Love Translation. All reserved.

E-mail: